| 4.66 -0.08 (-1.69%) | 06-15 09:38 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.11 |
1-year : | 7.14 |
| Resists | First : | 5.23 |
Second : | 6.11 |
| Pivot price | 4.3  |
|||
| Supports | First : | 4.28 |
Second : | 3.7 |
| MAs | MA(5) : | 4.23 |
MA(20) : | 4.39 |
| MA(100) : | 3.22 |
MA(250) : | 1.98 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 49.7 |
D(3) : | 33 |
| RSI | RSI(14): 60 |
|||
| 52-week | High : | 6.9 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ANTX ] has closed below upper band by 16.1%. Bollinger Bands are 25% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.86 - 4.88 | 4.88 - 4.89 |
| Low: | 4.4 - 4.42 | 4.42 - 4.43 |
| Close: | 4.71 - 4.74 | 4.74 - 4.76 |
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Sat, 13 Jun 2026
Number of shareholders of AN2 Therapeutics, Inc. – NASDAQ:ANTX - TradingView
Mon, 08 Jun 2026
Shareholders back AN2 Therapeutics (NASDAQ: ANTX) directors and auditor - Stock Titan
Thu, 04 Jun 2026
AN2 Therapeutics (Nasdaq: ANTX) posts strong early Chagas trial data - Stock Titan
Tue, 02 Jun 2026
AN2 Therapeutics (ANTX) officer sells 265 shares to cover RSU taxes - Stock Titan
Thu, 21 May 2026
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 36 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 18.9 (%) |
| Held by Institutions | 70.4 (%) |
| Shares Short | 1,210 (K) |
| Shares Short P.Month | 879 (K) |
| EPS | -1.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.5 % |
| Return on Equity (ttm) | -44.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -4.31 |
| PEG Ratio | 0 |
| Price to Book value | 2.08 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|